LLY241220P690000
- 0.34
- -0.11-24.44%
Eli Lilly and Co Newsroom
Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com
Broadcom rises over 8% again, with a cumulative increase of over 35% in two days! Which company will become the next member of the "trillion Market Cap club"?
After Broadcom's market cap exceeded one trillion dollars, there are currently nine companies in the "trillion-dollar market cap club" in the U.S. stock market, namely Apple, Microsoft, NVIDIA, Amazon, Google, Meta, Tesla, Broadcom, and Taiwan Semiconductor.
Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs. -- Barrons.com
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
Express News | Trump: 'We're Going to Knock Out the Middlemen' Who Are Keeping Drug Prices High
Express News | Trump: Does Not Like Mandates for Vaccines, When Asked Whether Schools Should Mandate
Express News | Trump: I'm a Big Believer in Polio Vaccine
Express News | Trump: Recently met with executives from Pfizer and Eli Lilly and Co.
Why the Investor Craze for Ozempic and Rival Weight-loss Drugs May Resume Next Year
EMA Panel Endorses Lilly's Omvoh for Expanded Use in Crohn's Disease
INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) have reached a commercialization agreement for "Jepalin" in mainland China.
INNOVENT BIO (01801.HK) and Eli Lilly and Co (LLY.US) announced a collaboration agreement regarding the rights of Eli Lilly’s non-covalent (reversible) BTK inhibitor "Jehpaili" (100 mg and 50 mg tablets) in mainland China. INNOVENT BIO will be responsible for the import, sale, promotion, and distribution of Jehpaili, while Eli Lilly will be responsible for the research and development and post-marketing medical affairs related work for Jehpaili. INNOVENT BIO's founder, Chairman and CEO Yu Dechao expressed great pleasure in further deepening the strategic cooperation with Eli Lilly, noting that Jehpaili is the latest generation, the first and only globally approved non-covalent (reversible) BTK inhibitor.
INNOVENT BIO (01801) has reached a commercialization cooperation with Eli Lilly and Co regarding a new cancer drug based on BTK inhibitors.
On December 16, INNOVENT BIO (01801) and Eli Lilly and Co jointly announced the following cooperation agreement regarding Eli Lilly's non-covalent (reversible) BTK inhibitor, Jaypalta (100 mg and 50 mg tablets), in mainland China: INNOVENT BIO will be responsible for the import, sales, promotion, and distribution of Jaypalta; Eli Lilly will be responsible for the research and development as well as post-marketing medical affairs related work.
Express News | Innovent Biologics Inc - Lilly to Manage R&D and Post-Market Medical Affairs for Jaypirca
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (Pirtobrutinib) in Mainland China
Eli Lilly and Co's blockbuster new drug "Tirzepatide" has filed its fifth marketing application in China.
On December 14, the latest announcement on the CDE website states that Eli Lilly and Co (LLY.US) has had its new indication application for the blockbuster drug GIP/GLP-1 receptor dual agonist tirzepatide injection accepted.
Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.50
Why Is Eli Lilly and Company (LLY) Among the Best Income Stocks to Buy According to Analysts?
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Eli Lilly's Mounjaro Won't Have Separate Indication for Obstructive Sleep Apnea, European Regulator Says
Eli Lilly's Manjaro Gains on Novo Nordisk's Wegovy in UK